Alnylam’s John Maraganore isn’t the only CEO to leave his post; CRISPR’s chief commercial officer takes the helm at a protein degradation player
The departure of a number of CEOs is the prevailing theme that kicks off this week’s installment: In a stunner, Alnylam CEO John Maraganore announced that Yvonne Greenstreet will be his successor at the end of the year. Maraganore, the Cambridge, MA biotech’s founding chief executive since 2002 who has helped invigorate the RNAi space, will step into a consulting role until March 31 and maintain his presence in the company as a member of the scientific advisory board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.